Slide 1: Financial Results Year Ended 31 December 2021
Financial Results Year Ended 31 December 2021
Slide 2: Vita Life Sciences Ltd
VITA LIFE SCIENCES LTD Vita Life Sciences is an Australian owned healthcare company listed, on the Australian Securities Exchange (ASX:VLS). Our core business is the development and distribution of over the counter (OTC) medicines, complementary and alternative medicines, dietary supplements and hea
Slide 3: Financial Commentary
FINANCIAL COMMENTARY • Record Group sales of $57.1m, up 23% on previous corresponding period (PCP). • Record net profit of $8.2m, up 41%. • Trading performance reflects ongoing demand for complementary GROUP SALES GROUP EBIT A$’m A$’m medicine across key markets. 60 13 • Supply chain disruption miti
Slide 4: Australian Operation
AUSTRALIAN OPERATION • Record revenue of $30.3m an increase of 46% on PCP. • Penetration into the Pharmacy channel combined with strong growth from the Health Food channel drove underlying Revenue up 46% EBIT up 56% performance. A$’m A$’m • Increased education and training initiatives supported broa
Slide 5: Education & Training
EDUCATION & TRAINING FINANCIAL RESULTS | YEAR ENDED 31 DECEMBER 2021 5
Slide 6: Malaysia
MALAYSIA • Record revenue of $19.2m an increase of 14% on PCP. • Increased consumer demand across the vitamin and Revenue up 14% EBIT up 33 % supplement category. A$’m A$’m • Whilst general trading conditions were challenging, traditional 20 selling channels remained active and open during Covid-19
Slide 7: Product Portfolio
PRODUCT PORTFOLIO FINANCIAL RESULTS | YEAR ENDED 31 DECEMBER 2021 7
Slide 8: Brand Activity
BRAND ACTIVITY FINANCIAL RESULTS | YEAR ENDED 31 DECEMBER 2021 8
Slide 9: Singapore
SINGAPORE Revenue up 14% A$’m EBIT down 10% • Revenue of $5.6m, an increase of 14% on PCP. A$’m 1 • Traditional selling channels were significantly disrupted by 6 0.8 Covid-19 “lockdowns” and limited tourism trade. 5 • A shift towards e-commerce platforms offset a reduction in 4 0.6 revenue from tra
Slide 10: Other Asia
OTHER ASIA Revenue down 48% • Revenue of $ 2.0m, a reduction of 48% on PCP. Covid-19 related A$’m trading conditions across Vietnam and Indonesia influenced the 5 performance. 4.5 4 • Vietnam remains a key strategic market. 3.5 3 • Thailand: A new business model was implemented, including the 2.5 2
Slide 11: Final Dividend & Cashflows
FINAL DIVIDEND & CASHFLOWS Gross operating cashflow Final dividend • Gross operating cashflow conversion to EBITDA was 75%. to EBITDA per share Stock holding levels were increased during the year to mitigate supply chain disruptions due to Covid-19. 3.1 120% • Fully franked final dividend declared o
Slide 12: Priorities & Outlook
PRIORITIES & OUTLOOK • The Company is implementing a three year (2021-2023) brand building investment strategy to drive higher consumer and retailer engagement via multiple channels. • Continue with an educational and digitally led marketing strategy to support the brands premium product positioning
Slide 13: Appendix
APPENDIX
Slide 14: Full Year Results
FULL YEAR RESULTS 2021 2020 Full year ended Dec $’m $’m Revenue 57.1 46.5 EBITDA 11.6 8.7 EBIT 11.2 8.1 Profit before tax 11.2 8.1 Profit after tax 8.2 5.9 EPS (Basic – cents/ share) 15.75 11.58 Dividend (cents / share) 5.75 4.25 FINANCIAL RESULTS | YEAR ENDED 31 DECEMBER 2021 14
Slide 15: Balance Sheet
BALANCE SHEET 2021 2020 Balance Sheet as at Dec $’m $’m Current assets 35.1 29.2 Non-current assets 10.2 9.9 Total assets 45.3 39.1 Current liabilities 14.5 13.0 Non-current liabilities 0.4 1.7 Total Liabilities 14.9 14.7 Net Assets 30.4 24.4 FINANCIAL RESULTS | YEAR ENDED 31 DECEMBER 2021 15
Slide 16: Cash Flow
CASH FLOW Cash Flow for the year ended Dec 2021 2020 $’m $’m Receipts from customers 60.2 50.2 Payments to suppliers and employees (51.4) (41.1) Gross operating cash flow 8.8 9.1 EBITDA 11.6 8.7 Gross operating cash flow / EBITDA 75.4% 104.6% Net interest 0 0 Income tax paid (2.9) (1.7) Operating ca
Slide 17: FINANCIAL RESULTS | YEAR ENDED 31 DECEMBER 2021
FINANCIAL RESULTS | YEAR ENDED 31 DECEMBER 2021 17
Slide 18: Disclaimer
DISCLAIMER This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to a